Partillion Bioscience

The company’s Nanovial technology allows massively parallel functional single-cell assays using standard flow cytometers. It enables high-throughput screening of hundreds of thousands to millions of individual cells based on secreted proteins or other functional readouts. The core application areas are antibody discovery from plasma B cells or hybridomas, with the ability to recover live cells post-screening for downstream sequencing or regrowth. The company has launched commercial kits such as Antibody Discovery Kits that streamline workflows in pharma/biotech R&D settings. No clinical results since it does not develop therapeutics.